The Loo-Riegelman absorption method provides the correct A~/V t value and the correct rate constant k~ (if absorption is first order), whether metabolism occurs in compartment
INTRODUCTION
= (C2)tn_ I -e -k21a' + kl2/k21, (C1)~._,(1 -e -k2'at) + k12 ACx At~2 (2) Although not explicitly stated in their article (1) , it is implicit that the asymptote of a plot of A,./V 1 is A~/VI, which is given by equation 3: A~/V~ = k~ Cj dt (3) 0
In equations 1-3, A,jV I is the cumulative amount of drug absorbed to time tn divided by the volume of the inner (central) compartment of Model II below (if drug is given by intravenous infusion it is the amount which has been infused to time t, divided by V~), (C~) t~ is the concentration of drug in the central compartment (assumed to be the equivalent of the plasma concentration), (C2)~, is the amount of drug in the outer so-called tissue compartment at time t, divided by the volume of the inner compartment (i.e., A2/VI), the integral is the area under the C 1 ,t curve from time to (when absorption commences) to time t,, and the rate constants k~2, k21, and ke~ refer to those of Model II below, In equation 3, A~/V 1 represents the total amount of drug absorbed divided by the volume l/~. Usually to is taken equal to zero since the integral is closely approximated by the trapezoidal rule, and, in such a case, one assumes (C~) = 0 when t = 0, where the latter is the time of dosing. Loo and Riegelman (1) showed that the A~./V~, t, data resulting from application of equations 1 and 2 could be analyzed to obtain the kinetics of input of drug to the bloodstream. This was shown by infusing an aspirin solution intravenously in man with a logarithmic infusion pump and backcalculating the first-order infusion rate. They also infused griseofulvin at a constant rate and acc~arately back-calculated the infusion rate. Subsequently, they reported (2) that when the interval between blood samples became too long the linear piecewise integration procedure used to estimate (C2)t, resulted in poor estimates, and they proposed a new equation which was based on a logarithmic piecewise procedure which they claimed solved the problem. Another variation in which the value of ket could be adjusted from the intravenous and oral experiments was reported (3).
The Loo-Riegelman method (1-3) is based on Model II below, but in a given practical situation one does not know whether the true model is Model I, Model II, or Model IlL Recently, Suzuki and Saitoh (4) showed that the result obtained by application of the Loo-Riegelman method was independent of the ratio of ke~,/k~l ~ if the true model was Model I. Kaplan (5) showed that for data collected on coumermycin A~ the absorption plot obtained by the Loo-Riegelman method, based on Model II, and the absorption plot, based on Model IIl, were identical, but they did not give
the reason for the result. Analogously, Breckenridge and Orme (6) applied both the Loo-Riegelman method, based on Model II, and the corresponding equations of Kaplan (5), based on Model III, to intravenous and oral warfarin plasma concentration data. They reported that the absorption plots obtained by the two methods were identical, but did not give the reason for the result. This report will show why these authors obtained the results that they reported.
In addition, the effect of bias on the estimates of k12, k21, and kei obtained from intravenous data on the result obtained by application of the Loo-Riegelman method to plasma concentrations observed in the same subject following oral administration has not been reported. Bias in such parameter estimates may exist either from (1) computer fitting of intravenous data using initial estimates of the parameters which are too distant from the real values, resulting in convergence at a local minimum, or (2) using graphical estimates of parameters, as has been shown by Wagner (7) and Wagner and Metzler (8) .
Since the Loo-Riegelman method assumes that the plasma concentration curve is linear between two adjacent points, then the interval or intervals between concentrations measured become very critical in the result attained with the method. This problem is examined further, and some suggestions are made to eliminate this problem as a major source of error.
EXPERIMENTAL AND RESULTS

Effect of Metabolism in Compartment 2
Define: AT = amount of drug absorbed to time T (same as A,, in equation 1).
C 2 = A2/V 1 = amount of drug in compartment 2 at time t/volume of compartment No. 1.
For Model I,
Since there is no way of knowing k~l 2 unless drug is measured in compartment 2 as well as in compartment 1, then one cannot apply these equations. Model II is assumed in applying the method of Loo and Riegelman (1):
fo Ar/V1 = (Cl)r + (C2)r + k~l Cl(t)dt (6) If the model is really Model II (i.e., elimination occurs only from compartment l), then the Loo-Riegelman method provides the correct asymptote (A~/Vi), the correct Ar/V ~ plot, and the correct values of k~2, k2~, and k,~. If the model is really Model ! and one applies Model 1I in the form of the Loo-Riegelman method, the method gives the correct asymptote (A~/k~), the correct Ar/V 1 vs. T plot (i.e., the correct kinetics of absorption are obtained), but only apparent values, (k12),p p, (k21)app, and (kel)app , of the disposition portion of the model are obtained, and not the real values, k12, k21, and kel I . The reason for this is as follows. When drug is administered intravenously as a bolus of dose D, the plasma concentration-time curve is described by the equation
Cl(t) = A e-~' + Be -~'
Formulas used to obtain estimates of microscopic rate constants give the following results:
(ka,)app = {Aft + Ba}/{A + B I (8) 
Hence
For Model I, working in amounts (A) Oral data were generated with the appropriate equation for Model I,
Ct(t) = A~ e -=' + A 2 e -e' + A 3 e -k~'
Cl(t ) = -23.4105 e -~ + 1t.9066 e -~176 + 11.5039 e -~ (33) 
Application of the Guggenheim Method to Estimate ko
The data for k, according to the Guggenheim method are shown in the last two columns of Table I 
Usual Methods of Estimating k~ and Co
Cl(t) = 29.758 e -~176 is, + 70.2419 e-1.703s,
Intravenous C1, t values were generated with equation 42 and 20 sets of concentrations "with noise" were generated by adding 5 ~o random error with normal deviates. Each of these 20 sets of concentration data was fitted to equation 41 using the program NONLIN and an IBM digital computer. The initial estimates used to initiate the iteration in each case were values of paper. Figure 1 consists of two semilogarithmic plots which show the nature of the trends. At the top of Fig. 1 is an expanded scale plot showing the data for the first 6 hr. At the bottom of Fig. 1 some of the data beyond 10 hr are plotted. A weighted residual plot would also show such systematic deviations. Oral C1, t data were generated by using the same real values of the disposition parameters as used to generate the original intravenous data. Three sets were generated using C o = 100 and k a = 0.5, C o = 75 and k~ = 1.25, and Co = 75 and k a = 2. The parameter values were substituted into equation 31 and the value of k21 = 0.515 was used for E 2. The LooRiegelman method was then applied to the C I , t data of each of the three sets using the biased parameters k12 = 1.853, k21 = 0.797, and k~ = 0.068. In each set, concentrations were used at times t = 0.2, 0.4, 0.6, 0.8. 1.0, 1.2, 1.4, The Guggenheim method was applied to the equally spaced AAT/V1, t I values (here tl is time at the beginning of the interval) in the 0-to 2-hr range, and the sigma-minus method was also applied to estimate A~/V~ and k, from each set of data. Results are shown in Table II . It may be seen that k~ is reasonably well estimated in each case but that A~/V~ is always appreciably higher than the real value. This is due to the bias in the fitting of the intravenous data. The ratio of volumes is 41/32.6 = 1.258, hence the ratio Table If . It is somewhat remarkable that k~ is estimated as well as it is under conditions of such biased estimates. This is accentuated by 
Effects of Time Interval Between Plasma Concentrations
Many simulations have been performed, but results of only one will be given. Table III in the last four columns. All calculations were carried out to the number of significant places shown in Table III . Although the trapezoidal areas are not listed, the error introduced by use of the trapezoidal rule in this simulation was of minor importance in determining the results. Since At appears in the exponent of "e" in two terms of equation 1, and both ACa and At appear in the third term, the value of At and its change with time are the major source of poor estimates of C2.
Simulation Example 3.
When a very large number of C1, t values are used, as in set I, ~2 is essentially the same as the real C 2 over the whole time range. However, in sets 2 and 3, when At suddenly jumps from 2 hr (in the 2-to 12-hr range) to 12 hr (between 12 and 24 hr) then the C2 estimated at 24 hr is appreciably lower than the real Cz value. At least with this set of data, when fewer "blood samples" are taken in the absorption phase (sets 3 and 4 compared with set 2) a similar dramatic effect on r is not seen. Of course, there is a lower limit, and one must take sufficient samples to get a good distribution of points at least up to the peak of the CI, t curve (which in this example is near 4 hr). Notice that although set 3 consists of 15 samples and set 4 consists of only 14 samples the C2 values are better in set 4 than in set 3. The large At of 24 hr (from 24 to 48 hr) in set 3 caused (~2 to become a large negative value at 48 hr.
AtjV 1 values for each set were estimated by applying equation 1, the trapezoidal rule for the areas, and the C a values listed in Table III In situations where the disposition parameters are biased, such as when they are obtained by the "feathering" or "back-projection" technique or when the computer converges on a local minimum in the least-squares surface, use of such biased parameters in application of the Loo-Riegelman method to oral data results in reasonable estimate of the true absorption rate, k, (if absorption is first order), but in a biased value of A2/V I which is approximately given by equation 44. This strongly suggests that in the fitting of the intravenous concentration data one should use as good initial estimates of the parameters k12, k21, ke~, and Co for Model II as possible, and fit the data to equation 41 repeatedly on the computer until one has the best curve-fit possible--that is, there should be no systemic deviations of the model-predicted C~ from the observed C~ values.
The reason there is bias when one "feathers" or "strips" the intravenous data is that to obtain the estimate of fl one assumes e -~t = 0 at some point and then for terminal concentration data assumes fl = -A In C/At. This biased estimate of fl is higher than the true value, hence the residuals are biased, and a biased estimate of ~ is also obtained. The amount of bias is very dependent on the particular set of data which is "stripped." Besides the usual definition of fi, one may define it as
When the digital computer obtains a fit without systematic deviations, it is really using this latter interpretation of fi rather than the former.
The Loo Riegelman method assumes that the plasma level curve is linear between adjacent points. Because of this assumption, the values of C2 estimated by the method depend on the time intervals between samples. Hence, optionally, in applying the method to oral concentration data one should have a large number of concentration time points which are closely spaced. But this is impractical since one can take only so many blood samples following any given treatment in a human subject. To circumvent the problem, one can fit a function or functions to the data points such that the "line" goes through each observed concentration and is "smooth" between observed concentrations. An ideal approach, which the author has studied, is use of the spiine and Akima methods reported by Fried and Zeitz (9) . With a very "steep-slope" plasma concentration curve (sum of four exponential terms), Sedman (personal communication) has shown that the method gives interpolated concentrations between adjacent "observed" points which differ only 0-2 ~o from the real values. Hence in applying the Loo-Riegelman method to oral concentration data one should generate a large number of such interpolated points and use these and the observed concentrations to estimate the C2 values. We now have a computer program to interpolate such values and apply equations 1 and 2 to the interpolated and observed values, z 2p. Larson and A. Sedman, University of Michigan, Ann Arbor, Mich.
In most simulations, the A,/V 1 value, and sometimes the k a value, is better estimated by means of the Guggenheim method from the early Ar/VI values than by the classical sigma-minus method. The Guggenheim method requires equally spaced Ar/V ~ values and hence equally spaced blood samples during the absorption phase. When using the curve-fitting method above, one can generate interpolated concentrations at equally spaced time values, and hence the blood samples need not actually be taken at equally spaced intervals to apply the Guggenheim method. However, if the operator wishes to insure that he used all observed concentrations in the absorption phase, then to apply the Guggenheim method the study should be designed for taking blood samples at equally spaced intervals at least up to the time of the expected maximum plasma concentration.
If absorption is not first order, then both the Guggenheim plot of log (AAtjVI) vs. t I and the sigma-minus plot will be curved if the data give a sufficient span of time compared with the time for half of the drug to be absorbed. In these cases, the user usually likes to present the A,n/V ~ vs. t plot. If only the observed concentration data are used, then the problem presented by simulation example 3 (Table IIl) may occur and the A~/V~ value may be difficult to determine. However, if one uses a large number of interpolated values, then an estimate close to the true value of A~/V 1 would be obtained: this is supported by set I in Table III . The relative A~/V~ values from different treatments are important in bioavailability studies and it is desirable to obtain the best possible estimates of this parameter.
